As knowledge of the stage and grade of a malignant tumor is essential for selection of the appropriate therapeutic modality and subsequent management of the patient, the patient's immunologic competence is equally significant. 'Immunostaging' is a trial method of assessing the immunocompetence of the host. In the present interim report a broad spectrum of cellular and humorally mediated parameters of immunologic responsiveness reflecting, with exception of inhibition of leukocyte migration by prostatic tissue extracts, general immunocompetence rather than tumor specific immunity were evaluated in 28 patients with prostatic cancer. These patients were then 'immunostaged' independently without prior knowledge of their clinical stage, and the correlation and significance of these determinations evaluated. A statistically significant correlation (P<0.01) was observed between the patients 'immunostage' and clinical stage of disease.
|Original language||English (US)|
|Number of pages||6|
|Journal||Current Therapeutic Research - Clinical and Experimental|
|State||Published - 1976|
ASJC Scopus subject areas
- Pharmacology (medical)